AURA

Aura Biosciences Inc

Sep 17 • 04:00PM ET

6.10

-0.19 -3.02 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP EDIT FATE ARVN ITCI KURA RVNC LITS

| Held by: VTI IWM VXF IBB IWN VTWO VHT IWO IWC DFAS

Index	RUT	P/E	-	EPS (ttm)	-1.96	Insider Own	33.11%	Shs Outstand	62.07M	Perf Week	-5.28%
Market Cap	378.93M	Forward P/E	-	EPS next Y	-2.02	Insider Trans	0.26%	Shs Float	41.55M	Perf Month	-8.82%
Enterprise Value	219.73M	PEG	-	EPS next Q	-0.46	Inst Own	68.21%	Short Float	6.72%	Perf Quarter	-1.29%
Income	-101.38M	P/S	-	EPS this Y	-17.24%	Inst Trans	67.27%	Short Ratio	15.20	Perf Half Y	-17.79%
Sales	0.00M	P/B	2.17	EPS next Y	1.35%	ROA	-47.97%	Short Interest	2.79M	Perf YTD	-25.79%
Book/sh	2.81	P/C	2.14	EPS next 5Y	-2.05%	ROE	-55.39%	52W High	12.38 -50.72%	Perf Year	-39.42%
Cash/sh	2.85	P/FCF	-	EPS past 3/5Y	-3.45% -11.09%	ROIC	-53.48%	52W Low	4.34 40.39%	Perf 3Y	-64.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.25% 5.18%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-9.14%	Oper. Margin	-	ATR (14)	0.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.39	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.43	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.39	EPS Q/Q	-13.47%	SMA20	-4.42%	Beta	0.45	Target Price	21.20
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	-8.01%	Rel Volume	1.34	Prev Close	6.29
Employees	106	LT Debt/Eq	0.09	Earnings	Aug 13 BMO	SMA200	-11.37%	Avg Volume	183.70K	Price	6.10
IPO	Oct 29, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.67% -	Trades		Volume	246,134	Change	-3.02%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Resumed	H.C. Wainwright	Buy	$22
Jul-25-24	Initiated	H.C. Wainwright	Buy	$21
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Apr-17-23	Resumed	BTIG Research	Buy	$38
Jul-19-22	Initiated	JMP Securities	Mkt Outperform	$26

Sep-03-25 07:00AM	Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-13-25 07:00AM	Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Jul-29-25 04:53PM	4 Artificial Intelligence Stocks (That Aren't Nvidia) You Can Buy and Hold for the Next Decade (Motley Fool)
May-15-25 09:32AM	Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants (GlobeNewswire) +5.71%
06:10AM	Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
06:01AM	Loading…
06:01AM	Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-01-25 04:01PM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-06-25 04:35PM	Is Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential? (Insider Monkey)
Apr-02-25 07:00AM	Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors (GlobeNewswire)
Mar-25-25 06:58PM	Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript) (SeekingAlpha) -15.40%
Mar-24-25 04:01PM	Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) -6.67%
07:00AM	Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress (GlobeNewswire)
Mar-03-25 07:00AM	Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress (GlobeNewswire)
Feb-25-25 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-26-24 08:00AM	Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
04:05PM	Loading…
Nov-12-24 04:05PM	Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Oct-17-24 04:05PM	Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial (GlobeNewswire) +14.09%
Sep-12-24 06:30AM	Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma (GlobeNewswire) +7.94%
Sep-03-24 04:05PM	Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 (GlobeNewswire) -7.04%
Aug-28-24 04:05PM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-24 04:05PM	Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting (GlobeNewswire)
Aug-08-24 07:00AM	Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jun-06-24 09:55AM	Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High? (Zacks)
May-30-24 04:05PM	Aura Biosciences to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 08:00AM	Aura Biosciences to Host Virtual KOL Event Pioneering a New Standard of Care In Ocular Oncology on May 29, 2024 (GlobeNewswire)
May-10-24 02:58PM	Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com)
May-09-24 01:55PM	AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-08-24 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-27-24 01:53PM	AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Loading…
07:00AM	Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-26-24 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Dec-11-23 09:55AM	Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet (Zacks) -8.46%
Dec-07-23 08:00AM	Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma (Business Wire)
Nov-23-23 09:55AM	Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade (Zacks)
Nov-09-23 04:05PM	Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +9.54%
Nov-08-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Nov-06-23 10:02PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire) -8.18% -32.55%
04:08PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
03:00PM	Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma (Business Wire)
Oct-31-23 04:05PM	Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023 (Business Wire) +9.24% +9.93%
Oct-02-23 04:05PM	Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments (Business Wire) -7.47%
Aug-09-23 07:00AM	Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -6.62%
Jul-31-23 06:07AM	Owning 38% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA), (Simply Wall St.)
May-24-23 04:05PM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire) -5.29%
May-12-23 07:00AM	Aura Biosciences to Participate in the JMP Securities Life Sciences Conference (Business Wire)
May-11-23 04:10PM	Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
May-03-23 07:52AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Mar-15-23 04:10PM	Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
11:11AM	Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth (Simply Wall St.)
Feb-16-23 10:43AM	Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate (Benzinga) -7.17%
07:00AM	Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration (Business Wire)
Feb-10-23 06:03AM	Why Shares of Aura Biosciences Jumped This Week (Motley Fool)
Feb-09-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Dec-24-22 09:27AM	Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 11% drop adds to a year losses (Simply Wall St.)
Dec-16-22 09:54AM	12 Stocks Insiders are Buying Now (Insider Monkey)
Nov-30-22 08:50PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire) -6.02%
04:01PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-24-22 06:34AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Nov-10-22 07:00AM	Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
06:45AM	Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma (Business Wire)
Nov-03-22 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Oct-06-22 10:12AM	Here's Why We're Not Too Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Situation (Simply Wall St.)
Oct-04-22 07:05AM	Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedicals Proprietary Suprachoroidal Space Platform (GlobeNewswire)
Oct-03-22 01:37PM	Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug (Benzinga) -19.48%
07:00AM	Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022 (Business Wire)
Sep-28-22 07:00AM	Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire) +19.23%
Sep-27-22 07:00AM	Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 (Business Wire) +5.12%
Sep-07-22 07:00AM	Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress (Business Wire)
Sep-01-22 07:00AM	Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress (Business Wire)
Aug-11-22 04:15PM	Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -8.60% +8.89%
Aug-02-22 07:00AM	Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference (Business Wire)
Jul-19-22 03:04PM	JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer" (Benzinga) +7.67%
Jul-17-22 08:36AM	Could The Aura Biosciences, Inc. (NASDAQ:AURA) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jun-30-22 08:51AM	Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate (MarketWatch) +12.73%
07:00AM	Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire)
Jun-23-22 08:44AM	Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer (Benzinga) -6.00%
Jun-22-22 04:30PM	Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma (Business Wire)
Jun-17-22 07:00AM	Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting (Business Wire) +6.92%
06:40AM	Bullish Aura Biosciences, Inc. (NASDAQ:AURA) investors are yet to receive a pay off on their US$716k bet (Simply Wall St.)
May-26-22 05:26PM	Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting (Business Wire)
May-25-22 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
May-12-22 04:15PM	Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +5.82%
May-03-22 04:05PM	Aura Biosciences Presents Preclinical Data Highlighting AU-011s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting (Business Wire)
07:00AM	Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference (Business Wire)
Apr-29-22 07:53AM	We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth (Simply Wall St.) +6.33%
Mar-23-22 04:15PM	Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
Mar-21-22 07:00AM	Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma) (Business Wire)
Mar-15-22 07:00AM	Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22 (Business Wire) +8.57%
Mar-08-22 04:30PM	Aura Biosciences to Present Preclinical Data Highlighting AU011s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting (Business Wire) +5.81%
Feb-28-22 07:00AM	Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference (Business Wire)
Feb-14-22 05:00PM	Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium (Business Wire) +13.09%
Feb-09-22 08:00AM	Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference (Business Wire)
Feb-03-22 01:38PM	Medicxi Ventures Management (Jersey) Ltd Buys Aura Biosciences Inc (GuruFocus.com)
Jan-29-22 07:52AM	What Percentage Of Aura Biosciences, Inc. (NASDAQ:AURA) Shares Do Insiders Own? (Simply Wall St.)
Nov-24-21 04:05PM	Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +11.36% +13.16%
Nov-23-21 04:05PM	Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference (Business Wire) -9.43%
Nov-15-21 11:00AM	Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting (Business Wire) +18.35%
Oct-28-21 09:39PM	Aura Biosciences Announces Pricing of Initial Public Offering (Business Wire)

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elazzouzi Amy	Senior Vice President, Finance	Aug 18 '25	Option Exercise	3.96	12,899	51,103	94,280	Aug 18 04:34 PM
Elazzouzi Amy	Senior Vice President, Finance	Aug 18 '25	Sale	6.70	7,722	51,737	86,558	Aug 18 04:34 PM
AMY F ELAZZOUZI	Officer	Aug 18 '25	Proposed Sale	6.70	7,722	51,751		Aug 18 04:20 PM
de los Pinos Elisabet	See Remarks	Jun 02 '25	Option Exercise	5.07	10,948	55,506	493,388	Jun 04 04:05 PM
Johnson David Michael	Director	May 16 '25	Buy	4.90	20,000	98,000	166,167	May 20 05:43 PM
Gibney Anthony S	See Remarks	May 16 '25	Buy	4.90	50,000	245,000	58,452	May 20 05:34 PM
Gibney Anthony S	See Remarks	May 16 '25	Sale	5.15	1,519	7,823	56,933	May 20 05:34 PM
Gibney Anthony	Officer	May 16 '25	Proposed Sale	5.15	1,519	7,823		May 16 04:57 PM
Elazzouzi Amy	Officer	Apr 16 '25	Proposed Sale	5.49	897	4,925		Apr 16 08:37 PM
Kilroy Conor	Officer	Apr 16 '25	Proposed Sale	5.49	7,162	39,319		Apr 16 08:37 PM
Elazzouzi Amy	Senior Vice President, Finance	Apr 16 '25	Sale	5.49	897	4,925	81,381	Apr 16 08:36 PM
Kilroy Conor	See Remarks	Apr 16 '25	Sale	5.49	7,162	39,319	179,313	Apr 16 08:36 PM
Plavsic Mark	Officer	Feb 18 '25	Proposed Sale	7.75	2,151	16,670		Feb 18 07:32 PM
Hopkins Janet Jill	Officer	Feb 18 '25	Proposed Sale	7.75	2,534	19,639		Feb 18 07:32 PM
Elazzouzi Amy	Officer	Feb 18 '25	Proposed Sale	7.75	1,404	10,881		Feb 18 07:32 PM
de los Pinos Elisabet	Officer	Feb 18 '25	Proposed Sale	7.75	20,221	156,796		Feb 18 07:31 PM
Plavsic Mark	Chief Technology Officer	Feb 18 '25	Sale	7.75	2,151	16,670	209,456	Feb 18 07:31 PM
Elazzouzi Amy	Senior Vice President, Finance	Feb 18 '25	Sale	7.75	1,404	10,881	82,278	Feb 18 07:31 PM
Hopkins Janet Jill	Chief Medical Officer	Feb 18 '25	Sale	7.75	2,534	19,638	269,794	Feb 18 07:30 PM
de los Pinos Elisabet	See Remarks	Feb 18 '25	Sale	7.75	20,221	156,796	482,440	Feb 18 07:30 PM
de los Pinos Elisabet	Officer	Jan 21 '25	Proposed Sale	7.67	15,955	122,381		Jan 21 09:10 PM
Elazzouzi Amy	Officer	Jan 21 '25	Proposed Sale	7.67	1,001	7,679		Jan 21 09:10 PM
de los Pinos Elisabet	See Remarks	Jan 21 '25	Sale	7.67	15,955	122,381	304,692	Jan 21 09:09 PM
Elazzouzi Amy	Vice President, Finance	Jan 21 '25	Sale	7.67	1,001	7,679	38,442	Jan 21 09:09 PM
Hopkins Janet Jill	Chief Medical Officer	Nov 18 '24	Sale	9.36	11,822	110,663	151,693	Nov 18 09:06 PM
Janet Jill Hopkins	Officer	Nov 18 '24	Proposed Sale	9.36	11,822	110,663		Nov 18 07:32 PM
Amy Elazzouzi	Officer	Oct 29 '24	Proposed Sale	10.74	553	5,938		Oct 29 08:38 PM
Elisabet de los Pinos	Officer	Oct 29 '24	Proposed Sale	10.74	9,200	98,788		Oct 29 08:33 PM
Julie B. Feder	Former Officer	Oct 29 '24	Proposed Sale	10.74	3,249	34,889		Oct 29 08:33 PM
de los Pinos Elisabet	See Remarks	Oct 29 '24	Sale	10.74	9,200	98,788	320,647	Oct 29 08:28 PM
Elazzouzi Amy	Vice President, Finance	Oct 29 '24	Sale	10.74	553	5,938	39,443	Oct 29 08:23 PM
Feder Julie B	Chief Financial Officer	Oct 18 '24	Option Exercise	3.44	25,131	86,532	159,407	Oct 21 06:23 PM
Feder Julie B	Chief Financial Officer	Oct 18 '24	Sale	12.03	25,131	302,361	134,276	Oct 21 06:23 PM
de los Pinos Elisabet	See Remarks	Oct 18 '24	Option Exercise	2.74	24,992	68,478	354,839	Oct 18 08:08 PM
de los Pinos Elisabet	See Remarks	Oct 18 '24	Sale	12.04	24,992	300,839	329,847	Oct 18 08:08 PM
JULIE FEDER	Officer	Oct 18 '24	Proposed Sale	10.29	25,131	258,598		Oct 18 04:21 PM
ELISABET DE LOS PINOS	Director	Oct 18 '24	Proposed Sale	10.29	24,992	257,168		Oct 18 04:21 PM
Plavsic Mark	Chief Technology Officer	Oct 16 '24	Sale	9.85	7,383	72,723	121,132	Oct 16 09:25 PM
Plavsic Mark	Officer	Oct 16 '24	Proposed Sale	9.85	7,383	72,723		Oct 16 09:22 PM
de los Pinos Elisabet	See Remarks	Sep 27 '24	Option Exercise	5.76	5,474	31,530	329,847	Oct 01 05:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AURA

Aura Biosciences Inc

Upgrade your FINVIZ experience